By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
PulseReporterPulseReporter
  • Home
  • Entertainment
  • Lifestyle
  • Money
  • Tech
  • Travel
  • Investigations
Reading: CEO Lars Fruergaard Jorgensen discusses Wegovy
Share
Notification Show More
Font ResizerAa
PulseReporterPulseReporter
Font ResizerAa
  • Home
  • Entertainment
  • Lifestyle
  • Money
  • Tech
  • Travel
  • Investigations
Have an existing account? Sign In
Follow US
  • Advertise
© 2022 Foxiz News Network. Ruby Design Company. All Rights Reserved.
PulseReporter > Blog > Money > CEO Lars Fruergaard Jorgensen discusses Wegovy
Money

CEO Lars Fruergaard Jorgensen discusses Wegovy

Pulse Reporter
Last updated: February 6, 2025 6:15 am
Pulse Reporter 6 months ago
Share
CEO Lars Fruergaard Jorgensen discusses Wegovy
SHARE


Novo Nordisk CEO Lars Fruergaard Jørgensen on Q4 results, Wegovy demand and drug pipeline outlook

It has been a rocky few months for Novo Nordisk.

Prescription knowledge from IQVIA suggests Novo’s weight problems drug Wegovy is shedding floor to rival Zepbound from Eli Lilly. Wegovy’s potential successor, CagriSema, got here up quick of investor expectations in a intently watched Section 3 trial. Novo’s inventory has fallen greater than 20% over the past yr, and other people feared issues would get even worse when the corporate launched fourth-quarter earnings and its 2025 outlook on Wednesday.

As an alternative, Novo beat fourth-quarter expectations and offered a gross sales development forecast between 16% and 24% – consistent with the 20% Wall Road was on the lookout for. Novo’s inventory rose greater than 4% on Wednesday.

In an interview with CNBC, Novo Chief Govt Officer Lars Fruergaard Jorgensen disregarded issues that Novo is falling behind Lilly.

“We’re fairly assured that as we transfer into the yr and we’ll be supplying increasingly of the starter doses, we will see a pleasant step up in our quantity and serving increasingly sufferers,” Jorgensen stated. “And the steerage we have now given for this yr, you’ll be able to say, testifies to an underlying important ramp in our enterprise. So we’re fairly assured each within the demand available in the market and in addition our means to provide and compete in that market.”

Jonathan Raa | Nurphoto | Getty Pictures

Individuals taking Wegovy begin off on the bottom dose – or the starter dose – then work their means as much as stronger formulations so their our bodies can get used to the drug. At instances, Novo has restricted the quantity of starter doses it shipped as a result of it struggled to make sufficient of the drug and needed to ensure individuals who had been already on the remedy might keep on it.

Novo’s 2025 gross sales steerage implies a 30% improve within the variety of sufferers taking one of many firm’s GLP-1 medication, corresponding to Ozempic, the corporate stated on its earnings name.

The corporate additionally tried to reassure traders about CagriSema’s effectiveness. Jorgensen stated some folks misplaced weight in a short time, and one other group misplaced weight constantly, displaying no signal of stopping by the point the trial ended, so they could want longer therapy.

“I am very assured within the efficiency of the biology we have now right here,” he stated.

Individuals are watching an earlier-stage therapy – amycretin – even nearer. That experimental drug lately confirmed promising leads to a section 1b/2a trial.

Jorgensen stated Novo is speaking to the FDA about probably transferring straight to a section three trial.

You Might Also Like

Gen Z has changed conventional job looking with TikTok—70% are discovering profession recommendation on social media

Train, together with common walks, boosts colon most cancers survival charges—and even rivals some medication, research reveals

MongoDB (MDB) This autumn earnings report 2025

Unredacted messages present Snapchat’s inaction on abuse, lawsuit claims

Trump’s stress on Apple to make All-American telephones ignores the final tech large that attempted and failed

Share This Article
Facebook Twitter Email Print
Previous Article Emilia Pérez Jacques Audiard On Karla Sofia Gascon Emilia Pérez Jacques Audiard On Karla Sofia Gascon
Next Article Issues to think about when reserving a company retreat — and why TPG selected Monterey Issues to think about when reserving a company retreat — and why TPG selected Monterey
Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Weekly Newsletter

Subscribe to our newsletter to get our newest articles instantly!

More News

Wolverine And Jack Reacher Are Made For Male Gaze
Wolverine And Jack Reacher Are Made For Male Gaze
13 minutes ago
Tesla Diner & Drive-In opens in California
Tesla Diner & Drive-In opens in California
44 minutes ago
The last word information to Viking cruise ships and itineraries
The last word information to Viking cruise ships and itineraries
46 minutes ago
Rom-Coms Single-Body Quiz
Rom-Coms Single-Body Quiz
1 hour ago
Chinese language startup Manus challenges ChatGPT in information visualization: which ought to enterprises use?
Chinese language startup Manus challenges ChatGPT in information visualization: which ought to enterprises use?
2 hours ago

About Us

about us

PulseReporter connects with and influences 20 million readers globally, establishing us as the leading destination for cutting-edge insights in entertainment, lifestyle, money, tech, travel, and investigative journalism.

Categories

  • Entertainment
  • Investigations
  • Lifestyle
  • Money
  • Tech
  • Travel

Trending

  • Wolverine And Jack Reacher Are Made For Male Gaze
  • Tesla Diner & Drive-In opens in California
  • The last word information to Viking cruise ships and itineraries

Quick Links

  • About Us
  • Contact Us
  • Privacy Policy
  • Terms Of Service
  • Disclaimer
2024 © Pulse Reporter. All Rights Reserved.
Welcome Back!

Sign in to your account